Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001628280-20-007783
Filing Date
2020-05-14
Accepted
2020-05-14 16:05:02
Documents
8
Period of Report
2020-03-31

Document Format Files

Seq Description Document Type Size
1 6-K auph-0331206xk.htm 6-K 17948
2 EXHIBIT 99.1 exhibit991-20200331interim.htm EX-99.1 570901
3 EXHIBIT 99.2 exhibit992-20200331mda.htm EX-99.2 394844
4 EXHIBIT 99.3 exhibit993-20200331certifi.htm EX-99.3 15880
5 EXHIBIT 99.4 exhibit994-20200331certifi.htm EX-99.4 15743
6 a2002aurinialogo.jpg GRAPHIC 121945
7 aurinialogoa08.jpg GRAPHIC 15156
8 aurinialogorbg031620v02.jpg GRAPHIC 121945
  Complete submission text file 0001628280-20-007783.txt   1367807
Mailing Address #1203-4464 MARKHAM STREET VICTORIA BC A1 V8Z 7X8
Business Address #1203-4464 MARKHAM STREET VICTORIA BC A1 V8Z 7X8 250-708-4272
Aurinia Pharmaceuticals Inc. (Filer) CIK: 0001600620 (see all company filings)

IRS No.: 000000000 | State of Incorp.: A0 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-36421 | Film No.: 20877698
SIC: 2834 Pharmaceutical Preparations